Screener
Alnylam Pharmaceuticals ALNY EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Alnylam Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
FAQ
- What is Alnylam Pharmaceuticals's EBITDA margin?
- Alnylam Pharmaceuticals (ALNY) reported EBITDA margin of 22% in Q2 2026.
- How has Alnylam Pharmaceuticals's EBITDA margin changed year-over-year?
- Alnylam Pharmaceuticals's EBITDA margin increased by 536.9% year-over-year, from -5% to 22%.
- What is the long-term trend for Alnylam Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's EBITDA margin has grown at a -37.8% compound annual growth rate (CAGR), from -161% to 15%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Alnylam Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude